|
Selected Industry Projects
Antihypertensive agents: amlopidine, ramipril - Phase 3 reports
Anti-infectives: azithromycin, linezolid - Phase 3 reports, quality control
Antiplatelet agent: clopidegrel - Phase 1 reports
Antithrombotic: factor Xa inhibitor - Phase 1 reports
Breast cancer: fulvestrant - Informed consent document
Diabetes: troglitazone - Phase 3 reports
Esophageal cancer: nimotuzumab - Protocol
Global Innovate!! implementation of progressive business ideas
Hormone replacement: norethindrone acetate/ethinyl estradial - Phase 3 reports
Hypercholesterolemia: torcetrapib / atorvastatin - Phase 2 reports
Neuropathic pain: gabapentin, pregabalin - Phase 3 reports, safety narratives
Renal disease: mycophenolate sodium - Protocol
Selective estrogen receptor modulator (SERM): lasofoxifene - Phase 2/3 reports
Smoking cessation: varenicline - Phase 3 reports
Workshops: Clinical Study Reports, GCP, ICH and the Declaration of Helsinki, Informed Consent, Search Strategies, Statistics in Medicine.
|
Salerno Scientific
Deborah F. Salerno, PhD
1530 Northwood Street
Ann Arbor, MI 48103 - USA
Tel + (734) 662-1572
info@SalernoScientific.com
|
